Every Form 4 that Omeros Corporation (OMER) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OMER and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OMER filings page.
For OMEROS CORP (OMER), VP and General Counsel Peter B. Cancelmo reported two exercise-and-sale transactions. On August 28 and August 31, 2026, he exercised stock options for a total of 50,000 shares of common stock at an exercise price of $2.94 per share and sold all 50,000 shares in the market at weighted average prices of $18.6451 and $18.5416, respectively. The sale prices are reported as weighted averages over multiple trades within disclosed intraday price ranges.
OMEROS CORP (OMER) director Arnold C. Hanish reported option exercises and related share sales. On August 26–27, 2026, he exercised stock options for 15,000 shares of common stock at exercise prices of $14.66 and $15.81 per share, then sold 15,000 shares in open-market transactions at weighted average prices between about $18.53 and $19.02 per share. A separate indirect holding of 12,400 shares is reported as held by the Arnold C. Hanish Living Trust, which has not sold these shares.
OMEROS CORP (OMER) reports that its VP, Finance & CAO, David J. Borges, exercised employee stock options and sold the resulting common shares. On August 21 and 24, 2026, he exercised options to acquire a total of 10,906 shares of common stock at exercise prices of $2.94 and $3.93 per share, then sold 10,906 shares of common stock in open-market transactions at prices of $18.95 and $19.10 per share.
The sales were made pursuant to a previously established Rule 10b5-1 trading plan adopted on February 10, 2026. The exercised options relate to grants that vest over 48 equal monthly installments starting April 1, 2022 and April 1, 2023, with expiration dates in 2032 and 2033. All transactions are reported as direct ownership; post-transaction share holdings are not specified in this filing.
OMEROS CORP (OMER) director Thomas J. Cable reported an option exercise-and-sale transaction. He exercised 15,000 Stock Options (Rights to Buy) for 15,000 shares of Common Stock at exercise prices of $2.00 and $3.93 per share, then sold 15,000 shares at a weighted average price of $18.4515 per share in multiple trades ranging from $18.23 to $18.72.
OMEROS CORP (OMER) reported that director Joseph L. Schocken received a grant of 30,000 stock options to purchase common stock. The options have an exercise price of $13.71 per share and expire on August 11, 2036. They vest in equal annual installments over three years beginning on the first anniversary of the grant date, and following this grant he holds 30,000 derivative securities directly.
Omeros Corp executive David J. Borges reported an option exercise and same-day sale of common stock. On August 13, 2026, he exercised 5,000 stock options with an exercise price of $3.93 per share, acquiring 5,000 common shares, and then sold 5,000 common shares at $16.95 per share in an open-market transaction. The filing states that the sale was made under a previously established Rule 10b5-1 trading plan, and that following the option exercise, 15,000 options of this grant remained outstanding, continuing to vest in equal monthly installments from a vesting commencement date of April 1, 2022.
Omeros Corporation reported that Chairman, CEO & President Gregory A. Demopulos received a grant of 1,000,000 stock options on July 22, 2026. The options have an exercise price of $9.84 per share, expire on July 22, 2036, and are exercisable into an equal number of common shares.
According to the vesting schedule, one-third of the options vest and become exercisable on August 1, 2027, with the remaining options vesting in 32 equal monthly installments on the first day of each month thereafter. Following this grant, he directly holds stock options for 1,000,000 shares.
Omeros Corp granted VP and General Counsel Peter B. Cancelmo 105,000 stock options for common stock on July 22, 2026. The options have a $9.84 per-share exercise price and expire on July 22, 2036. One-third vests on August 1, 2027, with the remaining shares vesting in 32 equal monthly installments thereafter.
Omeros Corp reported that its VP, Finance & CAO, David J. Borges received a grant of 105,000 stock options for common stock at an exercise price of $9.84 per share, expiring on July 22, 2036. One-third vests on August 1, 2027, with the remainder vesting in 32 equal monthly installments thereafter.
Omeros Corporation director Rajiv Shah received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $10.28 per share and expire on June 17, 2036. The award was made under Omeros’ non-employee director compensation policy in connection with the June 18, 2026 annual shareholder meeting.
The option will fully vest and become exercisable on the day before the company’s 2027 annual shareholder meeting, as long as Shah continues serving as a director through that date. Following this grant, he holds 15,000 stock options directly.
OMEROS CORP director Diana T. Perkinson received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $10.28 per share and were awarded under the company’s non-employee director compensation policy in connection with the June 18, 2026 annual shareholder meeting.
The option grant will fully vest and become exercisable on the day before the 2027 annual shareholder meeting, as long as she continues serving as a director through that date. Following this award, she holds 15,000 stock options directly.
OMEROS CORP director Leroy E. Hood received a routine stock option grant as part of non-employee director compensation. He was granted options to buy 15,000 shares of common stock at an exercise price of $10.28 per share, expiring on June 17, 2036. The option will fully vest and become exercisable on the day before the 2027 annual meeting of shareholders, provided he continues to serve as a director through that date.
Omeros Corporation director Arnold C. Hanish received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $10.28 per share and were awarded under the company’s non-employee director compensation policy in connection with the June 18, 2026 annual shareholder meeting.
The options will fully vest and become exercisable on the day before the 2027 annual shareholder meeting, as long as Hanish continues to serve as a director through that date. After this grant, he holds 15,000 stock options directly.
Omeros Corporation director Peter A. Demopulos received a grant of stock options to buy 15,000 shares of common stock at an exercise price of $10.28 per share. The options were awarded under the company’s non-employee director compensation policy and will fully vest the day before the 2027 annual shareholder meeting if he continues serving as a director.
OMEROS CORP director Thomas J. Cable received a grant of stock options covering 15,000 shares of common stock as board compensation. The options were awarded under the company’s non-employee director compensation policy in connection with the June 18, 2026 annual shareholder meeting.
The options have an exercise price of $10.28 per share and will fully vest on the day before the 2027 annual shareholder meeting, as long as Cable continues to serve as a director through that date. After this grant, he holds 15,000 stock options directly.
Omeros Corp director Thomas F. Bumol received a grant of stock options covering 15,000 shares of common stock as part of the company’s non-employee director compensation policy. The options have an exercise price of $10.28 per share and expire on June 17, 2036.
The award relates to the annual meeting of shareholders held on June 18, 2026. The option will fully vest and become exercisable on the day before the 2027 annual meeting of shareholders, provided he continues to serve as a director through that date.
Omeros Corp director Thomas J. Cable executed an options exercise-and-sale transaction involving 7,500 shares of common stock. He exercised stock options to acquire 7,500 shares at $10.84 per share, then sold 7,500 shares in open-market trades at a weighted average price of $11.6052 per share.
The sales were made pursuant to a previously established Rule 10b5-1 trading plan adopted on June 14, 2024, with the trading schedule set at that time. Following these transactions, Cable directly holds 35,067 shares of Omeros common stock. The options exercised were scheduled to expire on June 9, 2026, and the sale trades ranged in price from $11.46 to $11.93 per share.
Omeros Corporation’s Chairman, CEO & President Gregory A. Demopulos reported the exercise of stock options for 400,000 shares of common stock on February 18, 2026. The options, which vested over 48 monthly installments starting April 1, 2015, were exercised via a derivative conversion.
In connection with this exercise, 357,678 shares of common stock were withheld by Omeros to cover the exercise price and related tax liability, based on the closing stock price on February 17, 2026. The company states these withheld shares remained in its treasury and the transaction did not involve any open‑market sale.
Following the transactions, Demopulos directly owned 1,469,308 shares of common stock. Additional indirect holdings include 300,000 shares in each of two irrevocable gift trusts for his minor children and 123,945 shares held by his spouse, for which he disclaims beneficial ownership except to any pecuniary interest.
Omeros Corp executive David J. Borges, VP, Finance & CAO, reported option exercises and share sales in January 2026. On January 12, 2026, he sold 30,000 shares of common stock at a weighted average price of $12.72, leaving no common shares directly owned after that sale.
On January 13, 2026, Borges exercised a stock option for 30,000 shares at an exercise price of $3.06 per share and acquired those shares, then sold 30,000 shares the same day at a weighted average price of $12.3105, again ending with 0 common shares directly held. He continues to hold 65,000 stock options following these transactions.
The option referenced vests in 48 equal monthly installments starting on April 1, 2024. The filing notes that Borges has completed all currently planned sales of Omeros common stock.
Omeros (OMER) reported an insider transaction by Chairman, CEO & President Gregory A. Demopulos. On October 13, 2025, he made bona fide gifts of common stock—300,000 shares each—to two irrevocable trusts established for the benefit of his minor children at a reported price of $0 (transaction code G).
Following these gifts, he directly holds 1,426,986 shares. Indirect holdings include 300,000 shares in each child trust and 123,945 shares held by his spouse. He disclaims beneficial ownership of the trust and spouse shares except to the extent of any pecuniary interest.